XORTX Therapeutics
XRTX
4 hedge funds and large institutions have $161M invested in XORTX Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, reducing their positions, and 0 closing their positions.
2,004,184% more capital invested
Capital invested by funds: $8.01K → $161M (+$161M)
33% more funds holding
Funds holding: 3 → 4 (+1)
0.07% less ownership
Funds ownership: 0.07% → 0% (-0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$40.8M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$15.1K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$7.67K |
| 4 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
+$3.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$286 |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1 |
XRTX Hedge Fund Activity: Q4 2023 in Review
4 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q4 2023, worth a combined $161M — up 2,004,184% from $8.01K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XRTX positions and 0 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.
The largest buyer was DekaBank Deutsche Girozentrale, opening a new position worth an estimated $40.8M. The largest seller was Toronto Dominion Bank, cutting an estimated $286.
- 4 institutional investors held XORTX Therapeutics (XRTX) as of Q4 2023, up from 3 in Q3 2023.
- Funds reported $161M of XORTX Therapeutics stock for Q4 2023, up 2,004,184% quarter-over-quarter.
- 1 fund opened new XORTX Therapeutics positions in Q4 2023 and 0 closed out, a net change of +1 holder.
- The largest XORTX Therapeutics buyer in Q4 2023 was DekaBank Deutsche Girozentrale, an estimated $40.8M added.
- The largest XORTX Therapeutics seller in Q4 2023 was Toronto Dominion Bank, an estimated $286 sold.
Based on aggregated 13F filings for Q4 2023.